Reported 2 days ago
Stifel has reaffirmed its Buy rating and $48 price target for Bicara Therapeutics Inc. (NASDAQ:BCAX) following favorable ASCO data that highlighted significant outcomes for HPV-negative patients, such as a 21% complete response rate and a median overall survival of over 20 months. Despite competitor Merus also presenting strong data, analysts caution against drawing direct comparisons due to the non-randomized nature of the studies. Investors are encouraged to consider purchasing BCAX stock on any dips, pending more detailed results at future ASCO meetings.
Source: YAHOO